Literature DB >> 8732485

Synergistic stimulatory effects of tumour necrosis factor alpha and interferon gamma on replication of human immunodeficiency virus type 1 and on apoptosis of HIV-1-infected host cells.

X Han1, K Becker, H J Degen, H Jablonowski, G Strohmeyer.   

Abstract

Differential and sometimes contradictory effects have been described for tumour necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) on replication of human immunodeficiency virus type 1 (HIV-1). The authors examined individual and coordinate action of these cytokines on HIV-1 expression, and on apoptosis of HIV-1-infected host cells by determination of reverse transcriptase activity in cell culture supernatant, expression of HIV-1-RNA and production of p24 antigen in the promonocytic cell line U937 and its persistently HIV-1-infected clone U1. Apoptosis was demonstrated by typical cleavage of cellular DNA at internucleosomal regions in promonocytic and T-lymphocytic cell lines. TNF-alpha alone markedly stimulated HIV-1 replication in U1 cells at the transcriptional and on the translational level. Exclusive application of IFN-gamma only slightly enhanced HIV-1 expression, whereas it synergistically potentiated stimulatory effects of TNF-alpha. Both cytokines also synergistically induced apoptosis in HIV-1-infected host cells. Co-ordinate action of TNF-alpha and IFN-gamma is suggested to represent an important mechanism for disease progression in HIV infection. These findings demonstrate that cytokine effects on viral expression may vary depending on their single or combined application.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732485     DOI: 10.1046/j.1365-2362.1996.116271.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

Review 1.  Host genetic factors in susceptibility to HIV-1 infection and progression to AIDS.

Authors:  Koushik Chatterjee
Journal:  J Genet       Date:  2010-04       Impact factor: 1.166

2.  Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection.

Authors:  Philip J Norris; Brandee L Pappalardo; Brian Custer; Gerald Spotts; Frederick M Hecht; Michael P Busch
Journal:  AIDS Res Hum Retroviruses       Date:  2006-08       Impact factor: 2.205

3.  Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l.

Authors:  J J Lum; A A Pilon; J Sanchez-Dardon; B N Phenix; J E Kim; J Mihowich; K Jamison; N Hawley-Foss; D H Lynch; A D Badley
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis.

Authors:  J M Fakruddin; J Laurence
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 5.  Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines.

Authors:  Morgan A Reuter; Carolina Pombo; Michael R Betts
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

Review 6.  Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection.

Authors:  Lucy C K Bell; Mahdad Noursadeghi
Journal:  Nat Rev Microbiol       Date:  2017-11-07       Impact factor: 60.633

7.  Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis.

Authors:  T K Tarrant; P B Silver; J L Wahlsten; L V Rizzo; C C Chan; B Wiggert; R R Caspi
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

8.  Ingenol Protects Human T Cells From HIV-1 Infection.

Authors:  Kee-Jong Hong; Hak Sung Lee; Yeong-Shik Kim; Sung Soon Kim
Journal:  Osong Public Health Res Perspect       Date:  2011-08-03

Review 9.  Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

Authors:  Theodoros Kelesidis; Judith S Currier; Otto O Yang; Todd T Brown
Journal:  AIDS Rev       Date:  2014 Jul-Sep       Impact factor: 2.381

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.